FKBP1A and Glucose intolerance: NODAT represents a significant adverse effect of tacrolimus (TAC) therapy, with reported incidence rates reaching up to 53% in some studies [29], Glucose intolerance induced by calcineurin inhibitors is attributed to decreased insulin secretion, increased insulin resistance, and direct toxicity to pancreatic β-cells—the binding site of the tacrolimus-specific protein FKBP-12.